|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
21.04.26 - 17:48
|
Roche′s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD (GlobeNewswire EN)
|
|
|
Basel, 21 April 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new data from the Phase III METEOROID study demonstrating that ENSPRYNG® (satralizumab) reduced the risk of a new relapse by 68% compared to placebo in adults and adolescents with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), meeting its primary endpoint. The primary endpoint was measured by the time from randomisation to the first MOGAD relapse during the double-blind treatment period (p=0.0025). The results were shared today at a late-breaking oral presentation in the Clinical Trials Plenary Session at the 2026 American Academy of Neurology (AAN) Annual Meeting in Chicago....
|
|
|
|
|
|
|
|
|
|
|
21.04.26 - 07:03
|
FDA accepts application for Roche′s Gazyva/Gazyvaro for the treatment of the most common form of lupus (GlobeNewswire EN)
|
|
|
Basel, 21 April 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) for Gazyva®/Gazyvaro® (obinutuzumab) for the treatment of systemic lupus erythematosus (SLE). The filing acceptance is based on positive results from the phase III ALLEGORY study, which demonstrated a statistically significant and clinically meaningful benefit in the primary endpoint of SLE Responder Index 4 (SRI-4) at 52 weeks – a measure that assesses changes in disease severity, symptoms and physical condition.2 The FDA is expected to make a decision on an approval by December 2026. Gazyva/Gazyvaro is already approved for adults with lupus nephritis in the US and EU....
|
|
|
|
|
|
|
|
|
17.04.26 - 17:18
|
LA ROCHE-POSAY SPONSORS JANNIK SINNER...′S SHADOW (PR Newswire)
|
|
|
The dermatological skincare brand reframes the importance of sun protection through a new kind of sponsorship with "Shadow Sponsor", a culturally provocative idea PARIS, April 17, 2026 /PRNewswire/ -- In sports, athletes compete amidst a sea of logos. Sponsorship is everywhere. Logos......
|
|
|
|
|
16.04.26 - 15:30
|
Sciety portfolio company Saga Diagnostics acquired by Foundation Medicine, a subsidiary of Roche (Cision)
|
|
|
Sciety portfolio company Saga Diagnostics has entered into an agreement to be acquired by Foundation Medicine, Inc., a global precision medicine company and an independent subsidiary of Roche, for a deal value of up to USD 595 million, including commercial and regulatory milestone payments.
[image]
Saga Diagnostics is a biotechnology company developing advanced diagnostic methods to detect and monitor cancer after treatment. The company's technology is based on the analysis of tumour-specific structural variations in DNA from blood samples, in contrast to more traditional methods that...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
